Drug Safety

, Volume 33, Issue 7, pp 579–591

Incidence of Venous Thromboembolism in Users of Strontium Ranelate

An Analysis of Data from a Prescription-Event Monitoring Study in England
  • Vicki Osborne
  • Deborah Layton
  • Michael Perrio
  • Lynda Wilton
  • Saad A. W. Shakir
Original Research Article


Background: Strontium ranelate is indicated for the treatment of postmeno-pausal osteoporosis. An association between strontium ranelate and venous thromboembolism (VTE) was identified in an analysis of phase III clinical trials.

Objective: To estimate the incidence of VTE in patients within the strontium ranelate (Protelos®) Prescription-Event Monitoring (PEM) study cohort during the first 12 months after starting treatment.

Methods: Patients in this analysis were identified from dispensed prescriptions that had been issued by general practitioners (GPs) in England for strontium ranelate between October 2004 and January 2008. For each individual patient, a Green Form questionnaire was sent to their GP 12 months after the date of the first prescription issued for strontium ranelate, requesting information about the patient including start and stop dates of treatment (if stopped), age, sex, indication, any history of VTE events, reasons for stopping and whether the patient had any events since starting the drug. VTE was defined as reports of deep vein thrombosis (DVT) or pulmonary embolism (PE). The crude incidence of VTE was calculated for events that occurred during the first 12 months after starting treatment (plus 30 days after stopping), with 95% Poisson exact CIs for the whole cohort, and subsets defined by age and past history of VTE.

Results: The final analysis cohort consisted of 10 782 patients. Where specified, mean age was 73.3 years (SD 11.45) [n= 10 696]; 9833 (91.3%) were female and 934 (8.7%) were male. Where the history of VTE was specified, 233 patients (2.6%) had a history of VTE prior to starting. In the first 12-month period, there were 48 incident reports of VTE (DVT or PE) during treatment (or within 30 days of stopping) in the cohort, with 7696.89 years of exposure, giving a crude incidence rate of VTE of 6.24 cases (95% CI 4.60, 8.27) per 1000 patient-years exposed.

Conclusions: This analysis has provided an estimate of the incidence of VTE in patients treated with strontium ranelate in the general practice setting. The rate is similar to estimates in populations of similar age and corresponds to the incidence found in patients from phase III clinical studies and observational cohort studies of strontium ranelate on this topic. The crude annual incidence rate of VTE in the PEM cohort is higher than the background annual incidence rate found in the UK population, but is similar to estimates in populations of similar age and populations receiving treatment for post-menopausal osteoporosis. Also, we acknowledge the potential for underestimating the incidence in this population. Nevertheless, this analysis contributes to the ongoing postmarketing safety assessment of this product.


  1. 1.
    Servier Laboratories Limited. Protelos: summary of product characteristics. Servier, 2008 Jan 23 [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/15410/SPC/Protelos/ [Accessed 2010 May 12]
  2. 2.
    European Medicines Agency. Protelos (strontium ranelate): European public assessment report summary for the public. Doc. Ref.: EMEA/528138/2009 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/protelos/121604en6.pdf [Accessed 2010 May 12]
  3. 3.
    Halil M, Cankurtaran M, Yavuz BB, et al. Short-term hemostatic safety of strontium ranelate treatment in elderly women with osteoporosis. Ann Pharmacother 2007; 41(1): 41–5PubMedCrossRefGoogle Scholar
  4. 4.
    Grosso A, Douglas I, Hingorani A, et al. Post-marketing assessment of the safety of strontium ranelate: a novel case-only approach to the early detection of adverse drug reactions. Br J Clin Pharmacol 2008 Nov; 66(5): 689–94PubMedGoogle Scholar
  5. 5.
    Breart G, Cooper C, Meyer O, et al. Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database [online]. Available from URL: http://www.springerlink.com/content/c72l383648v82320/fulltext.pdf [Accessed 2010 May 12]
  6. 6.
    Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003; 70: 7–30PubMedCrossRefGoogle Scholar
  7. 7.
    Lopez JA, Kearon C, Lee AYY. Deep vein thrombosis. Hematology Am Soc Hematol Educ Program 2004; 439–56Google Scholar
  8. 8.
    Huerta C, Johansson S, Wallander MA, et al. Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Arch Intern Med 2007; 167: 935–43PubMedCrossRefGoogle Scholar
  9. 9.
    White RH. The epidemiology of venous thromboembolism. Circulation 2003; 107:I4–8PubMedCrossRefGoogle Scholar
  10. 10.
    Anderson F, Spencer FA. Risk factors for venous thromboembolism. Circulation 2003; 107:I-9-16CrossRefGoogle Scholar
  11. 11.
    Heit JA, Silverstein MD, Mohr DN, et al. Risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2000; 160: 809–15PubMedCrossRefGoogle Scholar
  12. 12.
    Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism. Arch Intern Med 2002; 162: 1245–8PubMedCrossRefGoogle Scholar
  13. 13.
    Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism Study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 1525–497CrossRefGoogle Scholar
  14. 14.
    Shakir SAW. Prescription-event monitoring. In: Mann RD, Andrews EB, editors. Pharmacovigilance. 2nd ed. Chichester: John Wiley & Sons Ltd, 2007: 307–16Google Scholar
  15. 15.
    Shakir S. Causality and correlation in pharmacovigilance. In: Talbot J, Waller P, editors. Stephens’ detection of new adverse drug reactions. 5th ed. Chichester: John Wiley & Sons Ltd, 2004: 329–43Google Scholar
  16. 16.
    CIOMS/WHO. International ethical guidelines for biomedical research involving human subjects. Geneva: CIOMS, 2002Google Scholar
  17. 17.
    Royal College of Physicians of London. Guidelines on the practice of ethics committees in medical research involving human subjects. 3rd ed. London: Royal College of Physicians of London, 1996Google Scholar
  18. 18.
    General Medical Council. Frequently asked questions supplement to ‘confidentiality: protecting and providing information’. London: General Medical Council, 2004: 9Google Scholar
  19. 19.
    Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158: 585–93PubMedCrossRefGoogle Scholar
  20. 20.
    Naess IA, Christiansen SC, Romundstad P, et al. Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 2007; 5(4): 692–9PubMedCrossRefGoogle Scholar
  21. 21.
    Tsai A, Cushman M, Rosamond W, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med 2002 May 27; 162: 1182–9PubMedCrossRefGoogle Scholar
  22. 22.
    Grady D, Ettinger B, Moscarelli E, et al. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation. Obstet Gynecol 2004 Oct; 104: 837–44PubMedCrossRefGoogle Scholar
  23. 23.
    Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006 Jul 13; 355(2): 125–37PubMedCrossRefGoogle Scholar
  24. 24.
    Daiichi Sankyo UK Ltd. Summary of product characteristics: Evista. Daiichi Sankyo UK Ltd, 2008 Sep 17 [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/595/SPC/Evista+60mg+film-coated+tablets/ [Accessed 2010 May 12]
  25. 25.
    Merck Sharpe & Dohme Ltd. Summary of product characteristics: Fosamax. Merck Sharpe & Dohme Ltd, 2009 Apr21 [online]. Available from URL: http://www.medicines.org.uk/EMC/medicine/1175/SPC/Fosamax/ [Accessed 2010 May 12]
  26. 26.
    Hallworth R. Prevention and treatment of postmenopausal osteoporosis. Pharm World Sci 1998; 20(5): 198–205PubMedCrossRefGoogle Scholar
  27. 27.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA 2002; 288(3): 321–33CrossRefGoogle Scholar
  28. 28.
    Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 Jan 29; 350(5): 459–68PubMedCrossRefGoogle Scholar
  29. 29.
    Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis. Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005; 90(5): 2816–22PubMedCrossRefGoogle Scholar
  30. 30.
    Spannagl M, Heinemann L, DoMinh T, et al. Comparison of incidence/risk of venous thromboembolism (VTE) among selected clinical and hereditary risk markers: a community-based cohort study. Thromb J 2005 Jul 20; 3: 8PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  • Vicki Osborne
    • 1
    • 2
  • Deborah Layton
    • 1
    • 2
  • Michael Perrio
    • 1
    • 2
  • Lynda Wilton
    • 1
    • 2
  • Saad A. W. Shakir
    • 1
    • 2
  1. 1.Research FellowDrug Safety Research UnitSouthamptonUK
  2. 2.University of PortsmouthPortsmouthUK

Personalised recommendations